WO1986002003A1 - Taurolidine in preoperative colon-disinfection - Google Patents

Taurolidine in preoperative colon-disinfection Download PDF

Info

Publication number
WO1986002003A1
WO1986002003A1 PCT/GB1985/000444 GB8500444W WO8602003A1 WO 1986002003 A1 WO1986002003 A1 WO 1986002003A1 GB 8500444 W GB8500444 W GB 8500444W WO 8602003 A1 WO8602003 A1 WO 8602003A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
colon
formula
taurolidine
orthograde
Prior art date
Application number
PCT/GB1985/000444
Other languages
French (fr)
Inventor
Rolf Wilhelm Pfirrmann
Original Assignee
Holmes, Michael, John
Ed Geistlich Sohne Ag Fur Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holmes, Michael, John, Ed Geistlich Sohne Ag Fur Chemische Industrie filed Critical Holmes, Michael, John
Publication of WO1986002003A1 publication Critical patent/WO1986002003A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Definitions

  • This invention relates to a novel method of disinfection of the colon in preparation for surgery.
  • Organisms present in the colon include such gram-negative bacteria as Escherio ⁇ hia Coli, Proteus spp. Streptococcus fae ⁇ alis, Bacteroides spp and anaerobic streptococci. These organisms carry endotoxins which are largely responsible for many of the harmful effects of sepsis and when released in large quantities, can produce endotoxic shock. Since most antibiotics, such as those previously used, tend to cause lysis of the bacterial cells, sterilisation using antibiotics can give rise to release of large quantities of endotoxin due to the high concentrations of bacteria present in the faeces (40-60%) .
  • R represents a hydrogen atom or an alkyl
  • R represents a hydrogen atom, an alkyl group having from 1 to
  • the invention thus includes the use of a compound of formula I as defined above, in particular taurolidine or taurultam, in the pre-operative disinfection of the interior of the colon.
  • a compound of formula I as defined above, in particular taurolidine or taurultam, in the pre-operative disinfection of the interior of the colon.
  • the active compound will in general convert invasive pathogens into non-invasive forms, as well as combatting bacterial toxins deriving from such pathogens.
  • the cleansing of the interior of the colon may be effected by the retrograde or, more preferably, by the orthograde technique.
  • the retrograde technique laxatives are generally required, followed by a series of enemas. This procedure may be carried out over several days. It is preferred, therefore. to use the orthograde technique, in which about 8-12 litres of an irrigation fluid are passed through the colon via the stomach, and such irrigation may be completed within 2-3 hours.
  • the irrigant is passed into the stomach continuously via a tube through the nose or mouth.
  • the enema solution or the irrigant may thus comprise, at least in part, a solution of the compound of formula I in water.
  • the solution will advantageously be approximately isotonic.
  • a solubilising agent for the compound of formula I may be present, for example a water- soluble long chain material such as polyvinyl pyrrolidone or gelatin.
  • an irrigant solution for orthograde disinfection of the colon comprising an aqueous solution containing 1-5% by weight of a compound of formula I as defined above, a long-chain solubiliser therefor and one or more sweetening and/or flavouring agents.
  • the overall dose administered will be about 20-30 gms.
  • a 2% solution of taurolidine •one litre will provide 20 grams while 1.5 litres will be required to provide 30 grams.
  • Such tablets or capsules will commonly contain 400 to lOOOmg, e.g. 500-700mg of the compound of formula I.
  • dosages stated for taurolidine should be multiplied by 1.5.
  • the compound of formula I will be absorbed systemically as well as acting locally against bacteria and toxins in the colon and will serve to combat any bacterial infections or toxaemia in the vascular system.
  • the active compound is effective prophylactically against post operative sepsis both locally and systemically.
  • orthograde -irrigation will be effected by passing a 3mm rubber or plastic tube into the stomach via the nose or mouth.
  • the patient is in a semi-sitting position on a so-called cholera- couch.
  • the irrigant solution will normally be isotonic saline or Ringer solution warmed to 37 ⁇ C and may be delivered through the stomach tube via a peristaltic pump.
  • the total quantity of irrigant will be 8-13 litres given over 2-3 hours. If the compound of formula I is given by drinking a further litre or more of liquid, somewhat less irrigant is preferable so that the total quantity of liquid does not exceed 13 litres.
  • Distilled water 200g 1000 tablets each containing 500mg taurolidine are produced by conventional means using the above formulation.
  • amylum maydis is replaced by 60g amylum orizae.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of an antibacterial and anti-toxaemic compound of the general formula (I), where R1 is hydrogen or a C1-5 alkyl group and R2 is hydrogen or a group of formula (II), for the preparation of an aqueous solution for the orthograde or retrograde preoperative disinfection of the colon. The preferred compound is taurolidine.

Description

Taurolidine in preoperative colon-disinfection
This invention relates to a novel method of disinfection of the colon in preparation for surgery.
Surgery carried out on the large bowel or colon is very frequently complicated by post-operative sepsis deriving from faecal organisms inhabiting the gut. In recent years, this problem has been reduced in part by mechanical cleaning of the colon, that is by washing.out its contents using retrogade irrigation (enemas) or orthgrade irrigation through a tube into the stomach via the nose or mouth. (J. Hewitt et al The Lancet, p.337, 1973). It has also been recommended to disinfect the colon using antibiotics such as neomycin and kanamycin in the irrigation fluid.
Organisms present in the colon include such gram-negative bacteria as Escherioσhia Coli, Proteus spp. Streptococcus faeσalis, Bacteroides spp and anaerobic streptococci. These organisms carry endotoxins which are largely responsible for many of the harmful effects of sepsis and when released in large quantities, can produce endotoxic shock. Since most antibiotics, such as those previously used, tend to cause lysis of the bacterial cells, sterilisation using antibiotics can give rise to release of large quantities of endotoxin due to the high concentrations of bacteria present in the faeces (40-60%) .
We have found that a particularly effective way of avoiding this is to use as antibacterial substance a methylol transfer antibacterial of the general formula
Figure imgf000004_0001
[wherein R represents a hydrogen atom or an alkyl
2 group having from 1 to 6 carbon atoms and R represents a hydrogen atom, an alkyl group having from 1 to
6 carbon atoms or a group of formula II
Figure imgf000004_0002
in which R is as defined above] .
"Particularly useful compounds of formula I are taurolidine (R 1=H, R2=Formula II) and taurultam
(R1=R2=H) .
The invention thus includes the use of a compound of formula I as defined above, in particular taurolidine or taurultam, in the pre-operative disinfection of the interior of the colon. Although it may be virtually impossible to kill all pathogens in the colon, the active compound will in general convert invasive pathogens into non-invasive forms, as well as combatting bacterial toxins deriving from such pathogens.
The cleansing of the interior of the colon may be effected by the retrograde or, more preferably, by the orthograde technique. In the retrograde technique, laxatives are generally required, followed by a series of enemas. This procedure may be carried out over several days. It is preferred, therefore. to use the orthograde technique, in which about 8-12 litres of an irrigation fluid are passed through the colon via the stomach, and such irrigation may be completed within 2-3 hours. The irrigant is passed into the stomach continuously via a tube through the nose or mouth.
The enema solution or the irrigant may thus comprise, at least in part, a solution of the compound of formula I in water. However, it is desirable to give the active compound at relatively high concentration after all or the greater part of the faeces has been washed out of the colon. It is thus preferable to give the active compound of formula I after the main body of irrigant has been administered, most simply by drinking an aqueous solution of the compound although it is also possible for the last litre or so of the irrigant to contain the active compound. The solution will advantageously be approximately isotonic. A solubilising agent for the compound of formula I may be present, for example a water- soluble long chain material such as polyvinyl pyrrolidone or gelatin. In the case of taurolidine, a 2% solution containing about 7.5% of Povidone BP (polyvinyl pyrrolidone) has been found to be approximately isotonic. Where it is desired to adjust the isotonicity of the solution, sodium chloride may be added (possibly together with a minor proportion of potassium chloride) . In the case of solution for drinking, one or more sweetening and/or flavouring agents are advantageously present.
According to a further feature of the invention we therefore provide an irrigant solution for orthograde disinfection of the colon comprising an aqueous solution containing 1-5% by weight of a compound of formula I as defined above, a long-chain solubiliser therefor and one or more sweetening and/or flavouring agents. In general, in the case of taurolidine the overall dose administered will be about 20-30 gms. Thus, where a 2% solution of taurolidine is given, •one litre will provide 20 grams while 1.5 litres will be required to provide 30 grams. If desired, however, it is possible to provide part of the overall dose of the active compound in solid form, e.g. in tablets or capsules, in order to reduce the amount of liquid to be drunk by the patient. Such tablets or capsules will commonly contain 400 to lOOOmg, e.g. 500-700mg of the compound of formula I. In the case of taurultam, dosages stated for taurolidine should be multiplied by 1.5.
The compound of formula I will be absorbed systemically as well as acting locally against bacteria and toxins in the colon and will serve to combat any bacterial infections or toxaemia in the vascular system. Thus, the active compound is effective prophylactically against post operative sepsis both locally and systemically.
In general, orthograde -irrigation will be effected by passing a 3mm rubber or plastic tube into the stomach via the nose or mouth. The patient is in a semi-sitting position on a so-called cholera- couch. The irrigant solution will normally be isotonic saline or Ringer solution warmed to 37βC and may be delivered through the stomach tube via a peristaltic pump. The total quantity of irrigant will be 8-13 litres given over 2-3 hours. If the compound of formula I is given by drinking a further litre or more of liquid, somewhat less irrigant is preferable so that the total quantity of liquid does not exceed 13 litres.
In irrigation studies in cats, the effect of a 2% solution of taurolidine was compared with that of a standard coloscopy solution in sterilising the colon in respect of Staphylococci, Streptococci, Enterobacteria, Lactobacillae, Clostridium perfringens, Bifidobacteria, anaerobic bacilli and the total anaerobic bacteria. It was found that a single retrograde irrigation with the 2% taurolidine solution was significantly more effective than a single and also a double orthograde irrigation with coloscopy solution. A double retrograde irrigation with taurolidine was even more effective. No adverse histological changes in the mucosa of the colon were observed. The taurolidine solution was particularly effective against the anaerobic bacteria, especially the gram negative bacteria.
The following Examples are given by way of illustration onlys-
Example 1 - Oral solution for orthograde sterilisation of the colon
Taurolidine 5.00g
Povidone BPC 18.75g
Saccharine
Flavouring Distilled water ad 250ml
Example 2 - Tablets
Taurolidine 500g
Am lum aydis 60g Kollidone 25 50g
(pol vinylpyrrolidone)
Plasdon XL 20g
Magnesium stearate 6g
Distilled water 200g 1000 tablets each containing 500mg taurolidine are produced by conventional means using the above formulation.
In an alternative tablet formulation, the amylum maydis is replaced by 60g amylum orizae.

Claims

- 6 -Claims
1. The use of an antibacterial and anti-toxaemic compound of the general formula (I)
Figure imgf000008_0001
where R is hydrogen or a C, - alkyl group and R 2 is hydrogen or a group of the formula
R'
Figure imgf000008_0002
for the preparation of an aqueous solution for the orthograde or retrograde preoperative disinfection of the colon.
2. The use as claimed in claim 1 in which the compound of formula (I) is taurolidine.
3. The use as claimed in claim 1 or claim 2 in which the aqueous solution contains 1-5% by weight of the compound of formula (I) , a long-chain stabiliser therefor and one or more sweetening and/or flavouring agents.
4. An irrigant solution for orthograde disinfection of the colon comprising an aqueous solution of
1-5% of a compound of formula (I) as defined in claim 1, a long chain stabiliser therefor and one or more sweetening and/or flavouring agents.
5. An irrigant solution as claimed in claim 4 comprising an aqueous solution contining taurolidine as the compound of formula (I) and polyvinyl pyrrolidone as the long chain stabiliser.
6. A compound of the general formula (I) as claimed in claim 1 for use in the orthograde or retrograde preoperative disinfection of the colon.
7. A method of preoperative disinfection of the colon in which the colon is irrigated by the orthograde or rectograde route with an aqueous solution of an effective amount of a compound of general formula (I) as claimed in claim 1.
8. A method as claimed in claim 1 in which the compound of formula (I) is taurolidine.
9. A method as claimed in claim 8 in which 20-30 g. of taurolidine is administered by the orthograde route.
10. A method as claimed in claim 9 in which a proportion of the compound of formula (I) is administered in solid form while the remainder is administered as an aqueous solution.
PCT/GB1985/000444 1984-09-28 1985-09-27 Taurolidine in preoperative colon-disinfection WO1986002003A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8424518 1984-09-28
GB848424518A GB8424518D0 (en) 1984-09-28 1984-09-28 Chemical compounds

Publications (1)

Publication Number Publication Date
WO1986002003A1 true WO1986002003A1 (en) 1986-04-10

Family

ID=10567398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1985/000444 WO1986002003A1 (en) 1984-09-28 1985-09-27 Taurolidine in preoperative colon-disinfection

Country Status (3)

Country Link
EP (1) EP0203933A1 (en)
GB (1) GB8424518D0 (en)
WO (1) WO1986002003A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010174032A (en) * 1998-01-08 2010-08-12 Ed Geistlich Soehne Ag Fuer Chemische Industrie Use of antimicrobial agent such as taurolidine or taurultam in manufacture of medicament to treat nosocomial microbial infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1458701A (en) * 1964-10-06 1966-03-04 Geistlich Soehne Ag Perhydro-1, 2, 4-thiadiazine-dioxides- (1, 1) and process for their preparation
FR2320101A1 (en) * 1975-08-04 1977-03-04 Geistlich Soehne Ag SOLUTIONS WITH IMPROVED ANTIBACTERIAL ACTION BASED ON THIADIAZINE DERIVATIVES
US4107305A (en) * 1975-08-04 1978-08-15 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of endotoxaemia
EP0139534A2 (en) * 1983-10-20 1985-05-02 Ed. Geistlich Söhne Ag Für Chemische Industrie Compositions for the prophylactic treatment of osteitis and osteomyelitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1458701A (en) * 1964-10-06 1966-03-04 Geistlich Soehne Ag Perhydro-1, 2, 4-thiadiazine-dioxides- (1, 1) and process for their preparation
FR2320101A1 (en) * 1975-08-04 1977-03-04 Geistlich Soehne Ag SOLUTIONS WITH IMPROVED ANTIBACTERIAL ACTION BASED ON THIADIAZINE DERIVATIVES
US4107305A (en) * 1975-08-04 1978-08-15 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of endotoxaemia
EP0139534A2 (en) * 1983-10-20 1985-05-02 Ed. Geistlich Söhne Ag Für Chemische Industrie Compositions for the prophylactic treatment of osteitis and osteomyelitis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 84, No. 7, 16 February 1976 (Columbus, Ohio, US) D.S. REEVES et al.: "Experimental Studies with an Antibacterial Substance, Taurolin.", see page 94, Abstract No. 39312n; & Prog. Chemother. (Antibacterial, Antiviral, Antineoplast.), Proc. Int. congr. Chemother., 8th 1973 (pub. 1974), 2, 583-6 *
Compr. Ther. (U.S.A.), Volume 5, No. 5, 1979, Chicago, Illinois, (US) D.L. ROSEMAN et al.: "Postoperative Abdominal Infections", pages 44-50 *
Helv. Chir. Acta, Volume 43, No. 5-6, 1976 S. MILIC et al.: "Bauchtrauma und Sepsis", pages 707-708, see page 708, the middle part of the page *
Helv. Chir. Acta, Volume 50, No. 1-2, 1983, Lausanne, (CH) C.H. RUEGSEGGER et al.: "Essai Comparatif Antibio-Prophylaxie Versus Taurolidine 1 Peri-Operatoire en Chirurgie Colique", pages 117-120, see Abstract; page 119, Discussion; page 120, Conclusions *
Journal of Applied Bacterialogy, Volume 41, No. 3, 1976 M.K. BROWNE et al.: "Taurolin, a new Chemotherapeutic Agent", pages 363-368, see Abstract; page 368 *
Rev. Med. Suisse Romande, Volume 102, No. 4, 1982 M.C. MARTI: "Progres en Chirurgie Colique et Prevention des Desunions Anastomotiques", pages 347-357, see page 354, right-hand column, results No. 3 *
Surg. Gynecol. Obstet, Volume 145, No. 6, December 1977 M.K. BROWNE et al.: "The in Vitro and in Vivo Activity of Taurolin against Anaerobic Pathogenic Organisms", pages 842-846 *
Surg. Gynecol. Obstet, Volume 146, No. 5, May 1978, (US) M.K. BROWNE et al.: "A Controlled Trial of Taurolin in Established Bacterial Peritonitis", pages 721-724, see page 724, summary *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010174032A (en) * 1998-01-08 2010-08-12 Ed Geistlich Soehne Ag Fuer Chemische Industrie Use of antimicrobial agent such as taurolidine or taurultam in manufacture of medicament to treat nosocomial microbial infection

Also Published As

Publication number Publication date
EP0203933A1 (en) 1986-12-10
GB8424518D0 (en) 1984-11-07

Similar Documents

Publication Publication Date Title
Bailey et al. Prevention of urinary-tract infection with low-dose nitrofurantoin
Zamora Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions
Tanaka et al. Antimicrobial activity of superoxidized water
US4626536A (en) Compositions for combatting toxaemia
JP2005511642A5 (en)
JPS62252725A (en) Antibacterial composition
US4337251A (en) Method of avoiding and removing adhesions
US20040072910A1 (en) AIDS prophylactic lubricating composition
Jelenko 3rd Silver nitrate resistant E. coli: report of case.
Stickler et al. The role of antiseptics in the management of patients with long-term indwelling bladder catheters
Lindsey et al. Effects of commonly used bowel preparations on the large bowel mucosal-associated and luminal microflora in the rat model
WO1986002003A1 (en) Taurolidine in preoperative colon-disinfection
US5662941A (en) Method for treating diseases caused by bacterial microorganisms with a composition containing fluorine F- and lithium LI+
DENNIS et al. Candida septicemia in the severely traumatized patient
Demetriades et al. Short-course antibiotic prophylaxis in penetrating abdominal injuries: ceftriaxone versus cefoxitin
Tulloch et al. Treatment of chronic furunculosis
Pulaski et al. Sterilization of the intestinal tract by antibiotics and supplemental agents
Gilmore et al. Prophylactic intraperitoneal povidone-iodine in alimentary tract surgery
Banks Acute pancreatitis: conservative management
Thatcher et al. Gonorrheal urethritis in males treated with a single oral dose of minocycline.
Wright et al. Aureomycin as an aid in abdominal surgery
Lally et al. Aminoglycoside peritoneal lavage: lack of efficacy in experimental fecal peritonitis
COYLE et al. Canine mycetoma: a case report and review of the literature
Wright et al. The clinical value of aureomycin: a review of current literature and some unpublished data
Neter et al. The combined antimicrobial activity of urea and sulfathiazole in urine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): GB JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985904844

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985904844

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1985904844

Country of ref document: EP